Syntekabio said on Thursday that it officially launched STB CLOUD, an AI new drug cloud platform service that applies its own cloud system based on its supercomputing infrastructure.

STB CLOUD is an AI new drug cloud platform service that works together with the AI synthetic new drug candidate discovery platform, DeepMatcher, and NGS analysis personalized precision medical platform NGS-ARS, without separate hardware or software in the cloud.

It supports DeepMatcher in the discovery of effective substances for AI synthetic new drugs and the NGS-ARS platform service for the genetic analysis of cancer and rare genetic diseases.

Connecting Deep Matcher through STB CLOUD can receive the results of the newly derived active drug substances within three weeks with just a few clicks, the company said.

This is expected to dramatically reduce the time and cost of new drug development for domestic and foreign pharmaceutical companies and researchers, said a Syntekabio official.

Syntekabio plans to provide cloud services by sequentially introducing its own AI platforms such as Neo-ARS, a new antigen prediction platform, PGM-ARS, a multivariate biomarker prediction and discovery platform into STB CLOUD. According to a company official, the global service is scheduled to be released next month and will target the global market, focusing on local subsidiaries in the U.S.

Syntekabio CEO Jung Jong-sun said, "We have greatly improved accessibility and speed to AI new drug development by combining Deep Matcher with NGS genomic analysis services in a cloud manner."

Jung added that his company will introduce the platform at home and abroad through STB CLOUD, including new drug development, precision medicine, and biomarker discovery, and will strengthen its position as a leader in the AI new drug development and precision medical industry.